Real-World Evidence

Alira Health Joins Forces with APMA to Advance Podiatric Registry

Retrieved on: 
Wednesday, March 27, 2024
Real-World Evidence, Partnership, RWE, Health, Patient, Research, Foot, Ankle, American Podiatric Medical Association, Surgeon, CAE, MPH, APMA, DPM, Physician, Pharmaceutical industry

Framingham, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Alira Health , a global advisory and clinical research firm, joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and ankle, as a corporate member to help advance APMA’s Podiatric Registry.

Key Points: 
  • Framingham, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Alira Health , a global advisory and clinical research firm, joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and ankle, as a corporate member to help advance APMA’s Podiatric Registry.
  • The APMA registry supports researchers’ understanding of diseases and ways to treat them.
  • "APMA is excited by the opportunity to drive powerful research to improve patient care in conjunction with Alira Health," said APMA Senior Medical Director Dyane E. Tower, DPM, MPH, MS, CAE.
  • “Our partnership with APMA marks an advancement in accelerating innovation and new solutions for patients,” said Gabriele Brambilla, CEO of Alira Health.

Florida Cancer Specialists & Research Institute Shares Pharmacy Expertise To Advance Medically Integrated Oncology Care

Retrieved on: 
Wednesday, April 3, 2024
Real-World Evidence, RN, Success, BP, RRMM, Doctor of Pharmacy, BCPS, Selinexor, Incidence, Partnership, Physician, Manufacturing, Bachelor of Pharmacy, DNP, Nursing, Prior authorization, Pharmacist, Roger Hawkins (drummer), CAPM, MPA, BSN, Therapy, RPH, Pharmacy, Outcome, Safety, Infrared spectroscopy correlation table, Best practice, FCS, PACS, OCN, Data, Metric, Health care

FORT MYERS, Fla., April 3, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) leaders and pharmacy experts will share insights and best practices in specialty pharmacy operations and dispensing that are contributing to positive patient outcomes at the NCODA 2024 Spring Forum in Dallas. The focus of the multi-day gathering, "Driving Optimal Strategies for Patient Care in Medically Integrated Oncology," is on the vital role of pharmacy involvement throughout the entire cancer care continuum.

Key Points: 
  • The focus of the multi-day gathering, "Driving Optimal Strategies for Patient Care in Medically Integrated Oncology," is on the vital role of pharmacy involvement throughout the entire cancer care continuum.
  • "Our Rx To Go team members continue to set the standard of excellence for medically-integrated oncology pharmacy and support services," said FCS President & Managing Physician Lucio Gordan, MD .
  • "They are well-equipped to contribute top-tier knowledge to help steer the future of oncology care."
  • NCODA is a globally recognized not-for-profit organization dedicated to building a patient-centered, medically integrated community of health care providers whose focus is to innovate the continuity of cancer care so that every patient receives the maximum benefit from their cancer treatment.

Florida Cancer Specialists & Research Institute Announces Formation of Healthcare Analytics Company

Retrieved on: 
Wednesday, March 27, 2024
Real-World Evidence, Genomics, Health, Data science, Practice management, Data analysis, EMR, Patient, Health care, Artificial intelligence, Radiology, Doctor of Philosophy, MD, Vita Nova, FCS, Data, Physician, Medical imaging

FORT MYERS, Fla., March 27, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) today announced the formation of a new healthcare analytics subsidiary. This new entity, named Vita Nova Insights, LLC d/b/a Vita Nova Insights,SM is wholly owned by Community Oncology Revitalization Enterprise, LLC (Core Ventures), FCS' management services organization, and was created to serve as a precision oncology insights and real-world evidence platform. By partnering with FCS to advance oncology research through the development of unique proprietary datasets combining advanced data curation, data science, artificial intelligence, and data analysis capabilities, Vita Nova Insights is positioned to bring differentiated insights to the marketplace.

Key Points: 
  • Vita Nova Insights,SM LLC to Provide Real-World Evidence, Platform Solutions & Analytics Support for Accelerating Improvements in Cancer Therapy Development & Patient Outcomes
    FORT MYERS, Fla., March 27, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) today announced the formation of a new healthcare analytics subsidiary.
  • Vita Nova Insights provides real-world evidence, platform solutions, analytics support to improve cancer care, outcomes.
  • "Healthcare analytics companies aren't new, " said FCS Chief Executive Officer Nathan H. Walcker .
  • This platform is unmatched – harmonizing analytics talent, deep and clinically rich longitudinal datasets, and a market-leading independent community oncology group.

Genesis Research Group Announces Appointment of David W. Miller as CEO

Retrieved on: 
Wednesday, March 6, 2024
Real-World Evidence, Acquisition, Doctor of Philosophy, Biotechnology, GSK, Growth, Senior advisor, RWE, Vice, GSK plc, Corporation, Research, Elan, Management

Prior to Genesis Research Group, David was Senior Vice President of Global Market Access at Biogen with responsibility for securing patient access to Biogen products worldwide.

Key Points: 
  • Prior to Genesis Research Group, David was Senior Vice President of Global Market Access at Biogen with responsibility for securing patient access to Biogen products worldwide.
  • David Miller, Chief Executive Officer of Genesis Research Group, said: “I am delighted to be leading Genesis Research Group as it continues to support some of the world’s leading pharmaceutical and biotechnology companies to innovate differently.
  • “On behalf of the entire Group, I want to thank Frank for his incredible service to Genesis Research Group and his leadership.
  • “It has been my honor to lead Genesis Research Group and I am extremely proud of the company it is today.

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

Retrieved on: 
Wednesday, February 28, 2024
Real-World Evidence, Cohort, KNSA, C-reactive protein, Rheumatoid factor, Recurrence, Investment, Telephone, Partnership, Growth, ID, Joint, Genentech, Roche, Rheumatoid arthritis, American College, Webcast, Patient, Pericarditis, Paradigm, Prescription, CD40, Pharmaceutical industry

HAMILTON, Bermuda, Feb. 28, 2024 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported fourth quarter and full-year 2023 financial results and recent portfolio execution.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $83.4 million, compared to $61.9 million for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were $83.3 million, compared to $55.8 million for the fourth quarter of 2022.
  • Net income for the fourth quarter of 2023 was $25.2 million, compared to net income of $4.5 million for the fourth quarter of 2022.
  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 28, 2024, to discuss fourth quarter and full-year 2023 financial results and recent portfolio execution.

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, March 5, 2024
Health Technology, Diabetes, Manufacturing, Technology, Pharmaceutical, Other Consumer, General Health, Medical Devices, Clinical Trials, Wearables, Mobile Technology, Other Manufacturing, Science, Consumer, Health, Research, Real-World Evidence, Cloud, OBE, Adolescence, Doctor of Philosophy, Treatment, Medical director, Database, University, Hypoglycemia, Associate, AID, University of Liverpool, Standard of care, Data, Therapy, Insulin, Convention, Randomized controlled trial, CGM, Pathway, Use, Conference, MDI, Automation, Endocrinology, MD, DASH, ATTD, Medicare, University of Edinburgh, Edge Hill University, Corporation, Chairperson, Medical device

“We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.

Key Points: 
  • “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
  • It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.
  • This presentation will take place on Thursday, March 7 at 12:00 p.m. CET and Friday, March 8 at 10:30 a.m. CET.
  • Insulet representatives will be available to provide Omnipod product demonstrations to conference attendees, offering healthcare professionals the chance to experience Omnipod DASH and Omnipod 5 first-hand.

Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.

Retrieved on: 
Tuesday, February 20, 2024
Data Management, Health, Technology, Health Technology, Software, General Health, Cardiology, Real-World Evidence, Woman, Cardiovascular disease, EHR, CVD, MDRX, Data, Heart failure, Prevalence, Natural language processing, Hypertension, BMI, Death, Patient, Natural language, Body mass index, LVEF, Coronary artery disease, NLP, Dietary supplement

Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.

Key Points: 
  • Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.
  • Using structured and unstructured data from the comprehensive Veradigm Network EHR dataset, the report presents cardiovascular condition prevalence by state and three-digit zip code.
  • Veradigm also examines the prevalence of cardiovascular conditions such as dyslipidemia/hyperlipidemia and hypertension in relation to body mass index (BMI) categories.
  • Veradigm has a variety of additional data sources including clinically enriched Veradigm Network EHR Data across various therapeutic areas and the Veradigm Cardiovascular and Metabolic Registries.

Digital Surgery Technologies Market Report 2024 - Improved Precision and Promising Post-Operative Rehabilitation through Pre-Surgical Planning

Retrieved on: 
Wednesday, March 6, 2024
Real-World Evidence, Investment, Name, Virtual reality, Hospital, University of Miyazaki, Algorithm, Privacy, AI, Education, Traction, Research, ROI, Digital, Pain, 3D, Growth, Johnson & Johnson, Use, Surgeon, Government, RWE, Country, Immersion, Health care, Interest, Patient, Region, Acceleration, Medicine, Patient safety, VR, Trust, Augmented reality, Microsoft, Software, Dentistry

The key factors driving the growth of the global digital surgery technologies market include the increasing interest of technologists and start-ups in surgery-related innovation, improved precision offered by digital surgery techniques, and promising post-operative rehabilitation through pre-surgical planning.

Key Points: 
  • The key factors driving the growth of the global digital surgery technologies market include the increasing interest of technologists and start-ups in surgery-related innovation, improved precision offered by digital surgery techniques, and promising post-operative rehabilitation through pre-surgical planning.
  • Increasing Investment and Funding for Digital Surgery Technologies: Digital surgery technologies, owing to their transformative potential to enhance precision, optimize workflows, and improve patient outcomes, are rapidly changing the landscape of healthcare.
  • Investing in digital surgery technologies is not just about financial gains; it's an investment in the future of healthcare.
  • Based on application, the digital surgery technologies market has been led by augmented reality and virtual reality, which held a 48.40% share in 2022.

Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research at 2024 MDA Clinical & Scientific Conference

Retrieved on: 
Friday, March 1, 2024
Real-World Evidence, Massachusetts General Hospital, Spirometry, Data mart, ALS, Doctor of Philosophy, Interim analysis, Edaravone, M.S, Hospital, Conference, Natural history, State university system, Abstract, CDM, SVC, MDA, Phase 4, Episcopal conference, MTPA, Pharmaceutical industry

JERSEY CITY, N.J., March 1, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.

Key Points: 
  • JERSEY CITY, N.J., March 1, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.
  • "These presentations reinforce our commitment to making a positive impact on the ALS community by better understanding disease markers and outcomes and providing important information on our treatment options for clinical practice."
  • Interim Analysis of the Radicava/Edaravone Findings in Biomarkers from ALS (REFINE-ALS) Study (James Berry, M.D., M.P.H.
  • Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients With Amyotrophic Lateral Sclerosis (Dung Pham, PhD; MTPA-CA)

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 16, 2024
Real-World Evidence, Labcorp, Acquisition, Cancer, Syneos Health, SAS Institute, Intelligence, Research, Investment, Real, Immunology, IBM, Drug development, Growth, EHR, Drug discovery, Conditional sentence, Neurology, RWE, Cognizant, Prevalence, Safety, PerkinElmer, IQVIA, Thermo Fisher Scientific, HTA, ChromeOS, Patient, Big data, ICON PLC, Environment, Market development, Partnership, Pharmaceutical industry

Real World Evidence Solutions Market Dynamics:

Key Points: 
  • Real World Evidence Solutions Market Dynamics:
    Key Market Players of Real World Evidence Solutions Industry:
    Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.